View all cases
APL 8326/2025
—·EP2501384: METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY
- Case details
- Status—ActionAppealCategoryMain Appeal
- Parties
- ClaimantsReps: Wim Maas (Taylor Wessing)
- Division
- Court of Appeal
- Judges
- Rian Kalden · Presiding judge and judge-rapporteur
- Ingeborg Simonsson · Legally qualified judge
- Patricia Rombach · Legally qualified judge
- Technology
- Organic Chemistry
- Language
- —
- First decided
- Apr 14, 2025
Decisions
- 2025-04-14Appeal decisionAppeal RoP220.2
The Court of Appeal reversed the first-instance order and granted Stadapharm access to the statement of claim and annexes filed by Accord in a now-withdrawn declaration of non-infringement action against Novartis, finding that following withdrawal of the main proceedings all parties consented and no confidentiality concerns remained apart from personal data redactions.
Legal issues:Public access to register (R.262.1(b) RoP)Third-party access to pleadingsSpecific interest in accessWithdrawal of main proceedings and effect on access
Documents
- 48F8CDF1B102C7C7FB250E00DDC4D0E1_en.pdf2025-04-14EN